Beacon Therapeutics
Clinical trials sponsored by Beacon Therapeutics, explained in plain language.
-
Gene therapy shot into both eyes aims to save sight in rare blindness
Disease control OngoingThis study tests a gene therapy called laruparetigene zovaparvovec (AGTC-501) in 10 males aged 12-50 with X-linked retinitis pigmentosa, a genetic condition that leads to vision loss. The therapy is injected into both eyes to deliver a working copy of the RPGR gene. The main goal…
Phase: PHASE2 • Sponsor: Beacon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Gene therapy offers hope for rare Blindness-Causing eye disease
Disease control OngoingThis study tests a gene therapy called AGTC-501 in males aged 12 to 50 with X-linked retinitis pigmentosa, a genetic eye disease that causes vision loss. Participants receive one of two doses of the therapy or no treatment, and researchers measure changes in vision under low ligh…
Phase: PHASE2, PHASE3 • Sponsor: Beacon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC